Production (Stage)
Avidity Biosciences, Inc.
RNA
$30.58
-$0.23-0.75%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -115.77M | -102.26M | -80.40M | -70.79M | -68.86M |
| Total Depreciation and Amortization | 785.00K | 738.00K | 710.00K | 687.00K | 641.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 13.40M | 7.81M | 8.07M | 9.16M | 8.17M |
| Change in Net Operating Assets | -23.24M | -6.16M | 6.01M | -4.06M | -10.34M |
| Cash from Operations | -124.83M | -99.87M | -65.62M | -65.00M | -70.38M |
| Capital Expenditure | -3.75M | -3.92M | -1.70M | -531.00K | -915.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 160.94M | -60.26M | -480.71M | -274.34M | -31.83M |
| Cash from Investing | 157.19M | -64.17M | -482.41M | -274.87M | -32.75M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 1.94M | 13.72M | 342.46M | 446.88M | 247.90M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 0.00 | 0.00 | -154.00K | 141.55M |
| Cash from Financing | 1.94M | 13.72M | 342.46M | 446.72M | 389.45M |
| Foreign Exchange rate Adjustments | 39.00K | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 34.34M | -150.32M | -205.56M | 106.85M | 286.32M |